Actinium Pharmaceuticals (ATNM) Competitors $1.62 -0.01 (-0.31%) As of 12:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNM vs. TRDA, TLSA, TNYA, SLS, MDWD, IPHA, EPRX, CCCC, DERM, and AARDShould you be buying Actinium Pharmaceuticals stock or one of its competitors? The main competitors of Actinium Pharmaceuticals include Entrada Therapeutics (TRDA), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), SELLAS Life Sciences Group (SLS), MediWound (MDWD), Innate Pharma (IPHA), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), Journey Medical (DERM), and Aardvark Therapeutics (AARD). These companies are all part of the "pharmaceutical products" industry. Actinium Pharmaceuticals vs. Its Competitors Entrada Therapeutics Tiziana Life Sciences Tenaya Therapeutics SELLAS Life Sciences Group MediWound Innate Pharma Eupraxia Pharmaceuticals C4 Therapeutics Journey Medical Aardvark Therapeutics Entrada Therapeutics (NASDAQ:TRDA) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership. Do institutionals and insiders have more ownership in TRDA or ATNM? 86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 7.6% of Entrada Therapeutics shares are held by company insiders. Comparatively, 6.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is TRDA or ATNM more profitable? Actinium Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Actinium Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics-92.30% -17.81% -14.55% Actinium Pharmaceuticals N/A -100.85%-47.89% Do analysts recommend TRDA or ATNM? Entrada Therapeutics currently has a consensus price target of $25.67, indicating a potential upside of 386.11%. Actinium Pharmaceuticals has a consensus price target of $4.50, indicating a potential upside of 178.64%. Given Entrada Therapeutics' higher probable upside, research analysts clearly believe Entrada Therapeutics is more favorable than Actinium Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to TRDA or ATNM? In the previous week, Entrada Therapeutics had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for Entrada Therapeutics and 0 mentions for Actinium Pharmaceuticals. Entrada Therapeutics' average media sentiment score of 0.78 beat Actinium Pharmaceuticals' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Entrada Therapeutics Positive Actinium Pharmaceuticals Neutral Which has more volatility and risk, TRDA or ATNM? Entrada Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.3, suggesting that its stock price is 130% less volatile than the S&P 500. Which has stronger earnings and valuation, TRDA or ATNM? Entrada Therapeutics has higher revenue and earnings than Actinium Pharmaceuticals. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$79.48M2.53$65.63M-$1.78-2.97Actinium PharmaceuticalsN/AN/A-$48.82M-$1.31-1.23 SummaryEntrada Therapeutics beats Actinium Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Actinium Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNM vs. The Competition Export to ExcelMetricActinium PharmaceuticalsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$50.38M$869.95M$5.71B$21.60BDividend YieldN/A4.84%5.53%3.52%P/E Ratio-1.161.2076.4129.57Price / SalesN/A121.10469.6059.26Price / CashN/A17.6437.4624.72Price / Book1.236.4813.134.57Net Income-$48.82M-$5.56M$3.29B$1.00B7 Day Performance0.31%1.68%2.40%0.55%1 Month Performance-7.18%5.82%4.42%2.65%1 Year Performance-10.77%26.09%73.40%14.09% Actinium Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNMActinium Pharmaceuticals2.1821 of 5 stars$1.62-0.3%$4.50+178.6%-12.0%$50.38MN/A-1.1630TRDAEntrada Therapeutics2.3407 of 5 stars$5.06-4.2%$25.67+407.2%-65.1%$200.84M$210.78M-2.84110TLSATiziana Life Sciences0.7776 of 5 stars$1.70+0.6%N/A+72.5%$197.47MN/A0.008News CoverageGap UpHigh Trading VolumeTNYATenaya Therapeutics2.6634 of 5 stars$1.20flat$6.25+420.8%-32.7%$195.57MN/A-1.25110SLSSELLAS Life Sciences Group1.2001 of 5 stars$1.68-9.2%$7.00+316.7%+42.9%$194.80M$1M-5.2510MDWDMediWound1.4237 of 5 stars$17.14-3.9%$32.25+88.2%+1.9%$192.81M$20.22M-6.4980News CoverageIPHAInnate Pharma2.7591 of 5 stars$2.07+3.3%$11.00+432.7%-17.5%$191.38M$12.62M0.00220Analyst RevisionGap UpEPRXEupraxia Pharmaceuticals2.1128 of 5 stars$5.30-0.4%$11.00+107.5%+101.4%$191.13MN/A-6.2429News CoverageCCCCC4 Therapeutics3.4839 of 5 stars$3.57+34.2%$8.67+142.8%-58.0%$189.31M$35.58M-2.26150Analyst ForecastGap UpHigh Trading VolumeDERMJourney Medical2.1289 of 5 stars$7.12+0.1%$12.17+70.9%+45.5%$187.06M$56.40M-18.7490Positive NewsAARDAardvark Therapeutics3.3126 of 5 stars$9.95+15.8%$32.60+227.6%N/A$186.38MN/A0.0018News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Tiziana Life Sciences Alternatives Tenaya Therapeutics Alternatives SELLAS Life Sciences Group Alternatives MediWound Alternatives Innate Pharma Alternatives Eupraxia Pharmaceuticals Alternatives C4 Therapeutics Alternatives Journey Medical Alternatives Aardvark Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ATNM) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
